Pros Holdings Inc (PRO) Stock News

A securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about product demand. The company allegedly used undisclosed discount programs to inflate handpiece unit sales, resulting in overstocking. PROCEPT's stock fell over 18% on February 25, 2026, when the company revealed that handpiece sales had consistently exceeded procedures. Investors have until September 22, 2026, to seek lead plaintiff status.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures. The company allegedly accumulated over 10,000 excess units in field inventory and was unable to achieve its 2025 guidance. The lead plaintiff deadline is September 22, 2026.

PROCEPT BioRobotics faces a securities class action lawsuit for allegedly failing to disclose material information about excess handpiece inventory and inflated sales figures during the Class Period (February 28, 2024 - February 25, 2026). The company is accused of misleading investors about U.S. handpiece sales that exceeded procedures, resulting in over 10,000 units of excess inventory that would cause significant revenue declines. Investors with losses exceeding $100,000 have until September 22, 2026 to file lead plaintiff applications.

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 - February 25, 2026). The firm is also pursuing cases against Hub Group, Inc. and investigating potential securities violations at Alignment Healthcare, Inc. Investors with losses are encouraged to contact the firm before respective deadlines.

Grabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging securities fraud. The company allegedly failed to disclose an extensive discount program that artificially inflated handpiece sales and revenues between February 2024 and February 2026. The undisclosed practices led to excess field inventory exceeding 10,000 units and significant stock price declines following quarterly earnings announcements. Shareholders who purchased PROCEPT securities during the class period have until September 22, 2026 to file a lead plaintiff motion.

Grabar Law Office has launched investigations into potential securities fraud and fiduciary duty breaches at four major companies: Erasca (ERAS) for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet (PODD) for defective manufacturing controls leading to voluntary product corrections; Power Solutions International (PSIX) for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics (PRCT) for using undisclosed discount programs that artificially inflated sales figures and created excess inventory.

Rosen Law Firm has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding sales practices. The lawsuit claims PROCEPT used undisclosed discount programs to artificially inflate handpiece unit sales and revenues, created excess inventory of over 10,000 units, and provided unrealistic 2025 guidance. Investors who purchased stock between February 28, 2024 and February 25, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is September 22, 2026.

Robbins Geller has filed a class action lawsuit against PROCEPT BioRobotics Corporation, alleging that the company and its executives made materially false and misleading statements regarding undisclosed discount programs that artificially inflated sales figures and created excess field inventory. The lawsuit covers investors who purchased PRCT stock between February 28, 2024 and February 25, 2026. Multiple stock price declines followed earnings announcements revealing lower-than-expected handpiece sales and inventory management issues.

Dimensional Fund Advisors Ltd. has disclosed a 1.26% interest in Prologis Inc, comprising 11,792,280 USD 0.01 common shares as of July 31, 2026. The disclosure includes recent purchases of 4,154 shares at prices around $144.10 per share. Dimensional also made concurrent disclosures regarding Segro PLC in relation to the same offer period.

Rosen Law Firm has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation on behalf of investors who purchased common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures and created excess inventory of over 10,000 units. The firm claims the company's 2025 guidance lacked a reasonable factual basis. Investors must move the court by September 22, 2026 to serve as lead plaintiff.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging the company issued materially false statements regarding its handpiece unit sales and revenues. The complaint claims PROCEPT used an undisclosed discount program to artificially inflate sales figures, created excess field inventory of over 10,000 units, and failed to disclose material risks. The lead plaintiff deadline is September 22, 2026.

Dimensional Fund Advisors Ltd. has disclosed a 1.26% interest in Prologis Inc, comprising 11,789,505 USD 0.01 common shares as of July 30, 2026. The disclosure includes recent purchases of shares at prices ranging from $145.36 to $146.19 per unit, along with a transfer of 1,225 shares. Dimensional expressly disclaims beneficial ownership and notes it lacks discretion over 260,784 of the disclosed shares.

iBUYPOWER, a gaming PC system integrator with 25 years of experience, has expanded into the professional workstation market with a new line of prebuilt and custom systems. The company simultaneously enhanced its warranty coverage to three years for both parts and labor, up from two years previously. The workstation lineup ranges from $3,349 to $19,149 and features configurations with Intel Core Ultra, AMD Ryzen, and high-end GPU options including NVIDIA RTX PRO Blackwell.

PROCEPT BioRobotics faces a securities class action lawsuit for allegedly failing to disclose material information about excess handpiece inventory and inflated sales figures during the Class Period (February 28, 2024 - February 25, 2026). Investors with losses exceeding $100,000 have until September 22, 2026 to file lead plaintiff applications.

Dimensional Fund Advisors Ltd. has disclosed a 1.26% interest in Prologis Inc, comprising 11,785,505 USD 0.01 common shares as of July 29, 2026. The disclosure includes a purchase of 1,241 shares at $145.47 per share and a transfer out of 1,915 shares. Dimensional also made disclosures regarding Segro PLC in relation to the same offer.

PROCEPT BioRobotics faces a securities class action lawsuit for failing to disclose material inventory issues. The company revealed on February 25, 2026 that handpiece sales had materially exceeded procedures since Q1 2023, resulting in over 10,000 units of excess field inventory. This disclosure caused the stock to decline approximately 18% in two days, from $27.84 to $22.69 per share. Investors who purchased shares between February 28, 2024 and February 25, 2026 can file lead plaintiff applications by September 22, 2026.

Rosen Law Firm has filed a class action lawsuit against PROCEPT BioRobotics Corporation on behalf of investors who purchased common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures and created excess inventory of over 10,000 units. The company allegedly failed to disclose these risks and was unable to achieve its 2025 guidance. Investors must move the court by September 22, 2026 to serve as lead plaintiff.

Dimensional Fund Advisors Ltd. has disclosed a 1.26% interest in Prologis Inc., comprising 11,789,090 USD 0.01 common shares as of July 27, 2026. The disclosure was made under Rule 8.3 of the Takeover Code, with recent dealings including purchases of 1,185 and 165 shares at prices of $147.50 and $147.26 respectively, plus a transfer in of 6,921 shares.

Grabar Law Office has initiated investigations on behalf of shareholders of four NASDAQ-listed companies: Cogent Communications (CCOI), EquipmentShare (EQPT), Photronics (PLAB), and PROCEPT BioRobotics (PRCT). The investigations allege breaches of fiduciary duties, including misrepresentation of business fundamentals, undisclosed related-party transactions, false demand statements, and artificially inflated sales figures. Shareholders who purchased shares before specified dates and still hold them may seek corporate reforms and damages at no cost.

A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation on behalf of investors who purchased stock between February 28, 2024 and February 25, 2026. The lawsuit alleges the company made materially false and misleading statements regarding business operations, growth prospects, and financial stability, causing stock prices to trade at artificially inflated levels. Investors suffered significant losses when the truth was disclosed.

Dimensional Fund Advisors Ltd. has disclosed a public opening position in Prologis Inc, holding 11,780,819 USD 0.01 common shares representing 1.26% of the company as of July 24, 2026. The disclosure was made on July 27, 2026, in accordance with Rule 8.3 of the Takeover Code. Dimensional also disclosed interests in Segro PLC in relation to the same offer.

Ferrari N.V. announced the completion of its second tranche of a €250 million share buyback program on the Euronext Milan and NYSE exchanges. Between July 20-24, 2026, the company purchased 57,800 common shares at an average price of €321.35. Since the program's inception in January 2026, Ferrari has repurchased 1,612,475 shares for a total consideration of €479.4 million as part of its multi-year €3.5 billion buyback initiative through 2030.

Peter Kendall has completed his mandate as Interim Chief Executive Officer of ARCpoint Inc. after 45 days, delivering his assessment and recommendations to the Board. His RSU grant has been pro-rated from 4 million to 2 million shares. The Board is now considering his recommendations and will seek to appoint a new CEO. Kendall will continue as an advisory consultant.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation, alleging that the company and its executives made materially false and misleading statements regarding sales practices. The lawsuit claims PROCEPT used undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess field inventory of over 10,000 units, and issued unrealistic guidance. Stock price declined significantly following earnings announcements in August 2025, November 2025, and February 2026.

Dimensional Fund Advisors Ltd. has disclosed a public opening position in Prologis Inc, holding 11,762,220 USD 0.01 common shares representing 1.26% of the company as of July 23, 2026. The disclosure includes recent purchases of 6,524 shares at $142.8150 and 641 shares at $145.1200, along with a transfer in of 702 shares. Dimensional notes it does not have discretion over 260,639 of the shares included in the total.

Helus Pharma announced completion of enrollment in its Phase 3 APPROACH pivotal study of HLP003, an investigational treatment for major depressive disorder, ahead of schedule. The study enrolled 223 participants with moderate to severe MDD who showed inadequate response to standard antidepressants. Topline data is expected in Q4 2026, with potential FDA New Drug Application submission targeted for 2028. The company also noted strong market demand for novel depression treatments, citing Johnson & Johnson's SPRAVATO sales growth.

Eva Live Inc. (NASDAQ: GOAI) announced a Letter of Intent to acquire a controlling 51% interest in Airbeam Wireless Technologies for approximately $16 million, with an option to acquire the remaining 49%. The acquisition provides access to over 260 patents and advanced millimeter-wave semiconductor technology built on more than $150 million in cumulative R&D investment. Eva Live aims to combine Airbeam's wireless technology with its AI platform to develop next-generation communications for autonomous drone swarms, resilient military networks, smart cities, and satellite infrastructure, targeting a $3 trillion global opportunity.

Dimensional Fund Advisors Ltd. has disclosed a 1.26% interest in Prologis Inc., comprising 11,748,636 USD 0.01 common shares as of July 16, 2026. The disclosure includes a purchase of 58,225 shares at $150.06 per share and a transfer in of 8,513 shares. Dimensional also made concurrent disclosures regarding Segro PLC.

Dimensional Fund Advisors Ltd. has disclosed a public opening position in Prologis Inc, holding 11,577,440 USD 0.01 common shares representing 1.24% of the company as of July 8, 2026. The disclosure includes a purchase of 406,142 shares at $47.2747 per share and a transfer in of 3,337 shares. Dimensional also made concurrent disclosures regarding Segro PLC.